Specht Sabine, Mand Sabine, Marfo-Debrekyei Yeboah, Debrah Alexander Yaw, Konadu Peter, Adjei Ohene, Büttner Dietrich W, Hoerauf Achim
Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany.
Parasitol Res. 2008 Nov;103(6):1303-9. doi: 10.1007/s00436-008-1133-y. Epub 2008 Aug 5.
The microfilaricidal and temporarily sterilizing drug ivermectin is used for mass treatment of filarial infections. Filariae containing Wolbachia endobacteria can also be treated by the antibiotic doxycycline. The loss of Wolbachia results in sterilization of Onchocerca volvulus and macrofilaricidal effects. Besides doxycycline, other antibiotics may be effective in depleting Wolbachia. A preliminary study on the effects of rifampicin on the endobacteria, embryogenesis and microfilariae production of O. volvulus was carried out in the year 2000 in Ghana. Twenty-six onchocerciasis patients were treated for 2 or 4 weeks with 10 mg/kg/day rifampicin. From 17 treated and nine untreated patients, all palpable nodules were extirpated 1 or 18 months after the start of the study and examined for Wolbachia and embryogenesis using immunohistology. One and 18 months after rifampicin treatment, the proportion of Wolbachia-positive worms was significantly reduced compared to the untreated group. In patients treated 4 weeks with rifampicin, only 21% and 18% of living female filariae contained Wolbachia after 1 and 18 months, respectively, compared to 92% in the untreated patients. The reduction of Wolbachia after 2 weeks rifampicin was less but also significant. Embryogenesis and microfilariae production were reduced after 4 weeks rifampicin treatment, rendering rifampicin an antibiotic with anti-wolbachial efficacy in human onchocerciasis. This treatment is less efficient than treatment with 6 weeks doxycycline, but might be an alternative for cases that cannot be treated with doxycycline, e.g. children, or might be further developed for combination therapy.
微丝蚴杀灭剂和临时绝育药物伊维菌素用于大规模治疗丝虫感染。含有沃尔巴克氏体内生菌的丝虫也可用抗生素强力霉素治疗。沃尔巴克氏体的缺失会导致盘尾丝虫绝育并产生杀成虫效果。除强力霉素外,其他抗生素可能对清除沃尔巴克氏体有效。2000年在加纳对利福平对盘尾丝虫的内生菌、胚胎发生和微丝蚴产生的影响进行了一项初步研究。26名盘尾丝虫病患者每天接受10mg/kg的利福平治疗2周或4周。在研究开始1个月或18个月后,从17名接受治疗和9名未接受治疗的患者身上切除所有可触及的结节,并用免疫组织学方法检查沃尔巴克氏体和胚胎发生情况。利福平治疗1个月和18个月后,与未治疗组相比,沃尔巴克氏体阳性虫体的比例显著降低。在接受利福平治疗4周的患者中,1个月和18个月后存活的雌虫中分别只有21%和18%含有沃尔巴克氏体,而未治疗患者中这一比例为92%。利福平治疗2周后沃尔巴克氏体的减少程度较小,但也很显著。利福平治疗4周后胚胎发生和微丝蚴产生减少,这表明利福平是一种对人类盘尾丝虫病具有抗沃尔巴克氏体功效的抗生素。这种治疗方法不如6周的强力霉素治疗有效,但对于不能用强力霉素治疗的病例(如儿童)可能是一种替代方法,或者可能进一步开发用于联合治疗。